TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

Daily Photo Galleries

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Positive economic, earnings reports return Dow, S&P 500 to record territory
  2. Highmark and UPMC feud over canceled physician contracts
  3. Oil, gas industry tries to keep talent in pipeline
  4. Small businesses’ dilemma: Keep costly health care coverage or lose talented workers
  5. Young watchmaker pursues lifelong fixation
  6. Variable-rate electricity contracts in Pennsylvania can cost customers plenty
  7. U.S. Steel reorganizes operating units
  8. Slow hunting, golf sales again drag down Dick’s profit
  9. Health care, gas drilling industries await Gov.-elect Wolf’s footprint
  10. Prosecutor warns of debt collection fraud ‘epidemic’
  11. Toyota to begin selling 1st fuel cell vehicle, Mirai, in December
Subscribe today! Click here for our subscription offers.